Patents Examined by Nizal Chandrakumar
  • Patent number: 9464033
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 11, 2016
    Assignee: ACUCELA INC.
    Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Patent number: 9457028
    Abstract: Abacavir, a nucleoside analog reverse transcriptase inhibitor, has been found to exhibit an anti-cancer activity on ATL cells in vitro without inhibiting DNA replication of normal cells. Abacavir or a pharmaceutically acceptable derivative thereof is useful as an active ingredient of a pharmaceutical composition for use in the prevention or the treatment of cancer, in particular a cancer whose DNA repair system is impaired such as breast cancer or adult T-cell leukemia.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: October 4, 2016
    Assignee: KYOTO UNIVERSITY
    Inventors: Akifumi Takaori, Shunichi Takeda, Masayuki Kobayashi, Kohei Tada
  • Patent number: 9457035
    Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: October 4, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Constantine G. Boojamra, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Oleg V. Petrakovsky, Adrian S. Ray, Lijun Zhang
  • Patent number: 9458124
    Abstract: Certain 3,6-disubstituted and 2,4,5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3,6 and 2,4,5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: October 4, 2016
    Assignee: Wayne State University
    Inventor: Aloke K. Dutta
  • Patent number: 9453037
    Abstract: The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 27, 2016
    Assignee: KEMPHARM, INC
    Inventors: Sven Guenther, Guochen Chi, Bindu Bera, Travis Mickle, Sanjib Bera
  • Patent number: 9452153
    Abstract: Provided are amine derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 27, 2016
    Assignee: ACUCELA INC.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Thomas L. Little, Jr., Ryo Kubota
  • Patent number: 9447112
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 20, 2016
    Assignee: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 9446033
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 20, 2016
    Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida
  • Patent number: 9440940
    Abstract: Methods for the synthesis of psoralen derivatives are provided.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Macopharma, S.A.S.
    Inventor: Bernard Refouvelet
  • Patent number: 9440974
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 13, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Patent number: 9434756
    Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: September 6, 2016
    Assignee: medac Gesellschaft für klinische Spezialpräparate mbH
    Inventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
  • Patent number: 9428494
    Abstract: The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. Compounds of the invention are useful to modulate (e.g. agonize or antagonize) opioid receptor function.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: August 30, 2016
    Assignee: University of Iowa Research Foundation
    Inventor: Thomas Prisinzano
  • Patent number: 9428514
    Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 30, 2016
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Warren M. Kati, Keith F. McDaniel, Chang H. Park, George S. Sheppard, Le Wang
  • Patent number: 9427415
    Abstract: Compounds and methods for modifying sensory perception associated with transient sensory receptors TRPA1, TRPV1, and TRPA1V1. A method for screening compounds for modulation of TRPA1, TRPV1, and/or TRPA1V1. Compositions comprising TRPA1V1 agonists or antagonists, for modifying sensory perception of the compositions.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 30, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Koti Tatachar Sreekrishna, Yakang Lin
  • Patent number: 9428484
    Abstract: The present invention relates to a method for the production of cyclic carboxylic acid esters, in particular intramolecular lactones, such as e.g. dilactide, the production of these cyclic esters from oligomeric carboxylic acids being effected by cyclizing depolymerization. During this reaction, a condensation product of these oligomeric carboxylic acids is produced as by-product, i.e. a mixture of higher-molecular oligomeric carboxylic acids which are hydrolyzed in a further step and hence recovered. This hydrolysate can be added again to the cyclizing depolymerization which is implemented in the first step.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: August 30, 2016
    Assignee: UHDE INVENTA-FISCHER GMBH
    Inventors: Caspar Paetz, Udo Muehlbauer, Habib Driouch
  • Patent number: 9422275
    Abstract: Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R?, X, or NR1R2; R? is R3, or OR3; R? is R4, or OR4; R1 and R2 are each independently H, alkyl, or acyl; R3 is H, heteroaryl, or alkyl; R4 is H, heteroaryl, or CnH2n+1 (n>2); and X is F, Br, I, CN, or NO2. In some embodiments, compounds having a molecular structure according to Formula 1 have the property of inhibiting a growth of a cell line selected from HeLa and MB468 with a sub-micromolar IC50.
    Type: Grant
    Filed: July 19, 2014
    Date of Patent: August 23, 2016
    Assignee: The Regents of the University of California
    Inventors: Wen-Hwa Lee, Jiewen Zhu, Chun-Mei Hu
  • Patent number: 9423323
    Abstract: Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 23, 2016
    Assignee: Life Technologies Corporation
    Inventors: Wai-Yee Leung, Ching-Ying Cheung, Stephen Yue
  • Patent number: 9422310
    Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 23, 2016
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
  • Patent number: 9422313
    Abstract: Methods include formation of 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol esters. The method comprises contacting a 1-chloro-3-fluoro-2-substituted benzene with an alkyl lithium to form a lithiated 1-chloro-3-fluoro-2-substituted benzene. The lithiated 1-chloro-3-fluoro-2-substituted benzene is contacted with an electrophilic boronic acid derivative to form a 4-chloro-2-fluoro-3-substituted-phenylboronate. The 4-chloro-2-fluoro-3-substituted-phenylboronate is reacted with an aqueous base to form a (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate. The (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate is reacted with an acid to form a 4 chloro-2-fluoro-3-substituted-phenylboronic acid. The 4-chloro-2-fluoro-3-substituted-phenylboronic acid is reacted with 2,3-dimethyl-2,3-butanediol to form 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol esters .
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: August 23, 2016
    Assignee: Dow AgroSciences LLC
    Inventor: Jossian Oppenheimer
  • Patent number: 9422280
    Abstract: The invention relates to N-substituted hetero-bicyclic compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to methods and uses of these N-substituted hetero-bicyclic compounds, and of compositions comprising thereof, for combating and controlling animal pests. Furthermore the invention relates also to pesticidal methods of applying such N-substituted hetero-bicyclic compounds. The N-substituted hetero-bicyclic compounds of the present invention are defined by the following formula I: wherein A, B, X, Het, R1, R2, W1, W2, W3 and W4 are defined as in the description.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: August 23, 2016
    Assignee: BASF SE
    Inventors: Nina Gertrud Bandur, Ralph Paulini, Florian Kaiser, Arun Narine, Joachim Dickhaut, Karsten Körber, Wolfgang Von Deyn, Swetlana Derksen, Deborah L. Culbertson, Nancy B. Rankl